nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—PKMYT1—melanoma	0.215	0.418	CbGaD
Dasatinib—EPHA2—melanoma	0.149	0.29	CbGaD
Dasatinib—PDGFRA—melanoma	0.0604	0.117	CbGaD
Dasatinib—KIT—melanoma	0.0443	0.0861	CbGaD
Dasatinib—CYP1B1—melanoma	0.0356	0.0691	CbGaD
Dasatinib—ABCG2—Vemurafenib—melanoma	0.028	0.169	CbGbCtD
Dasatinib—CYP1B1—Docetaxel—melanoma	0.0202	0.122	CbGbCtD
Dasatinib—CYP1A1—Dacarbazine—melanoma	0.0198	0.119	CbGbCtD
Dasatinib—ABCG2—Dactinomycin—melanoma	0.0186	0.112	CbGbCtD
Dasatinib—CYP1A2—Carmustine—melanoma	0.0146	0.088	CbGbCtD
Dasatinib—CYP1A2—Vemurafenib—melanoma	0.0116	0.0696	CbGbCtD
Dasatinib—CYP3A4—Temozolomide—melanoma	0.0111	0.0665	CbGbCtD
Dasatinib—ABCB1—melanoma	0.0102	0.0198	CbGaD
Dasatinib—ABCG2—Docetaxel—melanoma	0.00962	0.0579	CbGbCtD
Dasatinib—CYP1A2—Dacarbazine—melanoma	0.00886	0.0533	CbGbCtD
Dasatinib—ABCB1—Dactinomycin—melanoma	0.00672	0.0404	CbGbCtD
Dasatinib—CYP3A4—Vemurafenib—melanoma	0.00606	0.0365	CbGbCtD
Dasatinib—CYP3A5—Docetaxel—melanoma	0.00533	0.0321	CbGbCtD
Dasatinib—ABCB1—Docetaxel—melanoma	0.00347	0.0209	CbGbCtD
Dasatinib—CYP3A4—Docetaxel—melanoma	0.00208	0.0125	CbGbCtD
Dasatinib—PTK6—skin epidermis—melanoma	0.00181	0.0293	CbGeAlD
Dasatinib—PTK6—hair follicle—melanoma	0.00129	0.0209	CbGeAlD
Dasatinib—PKMYT1—neck—melanoma	0.000947	0.0153	CbGeAlD
Dasatinib—LIMK2—hair follicle—melanoma	0.000858	0.0139	CbGeAlD
Dasatinib—CSK—hair follicle—melanoma	0.000826	0.0134	CbGeAlD
Dasatinib—EPHB1—eye—melanoma	0.000818	0.0133	CbGeAlD
Dasatinib—EPHB1—retina—melanoma	0.000811	0.0131	CbGeAlD
Dasatinib—RIPK2—endothelium—melanoma	0.00078	0.0126	CbGeAlD
Dasatinib—ERBB3—hair follicle—melanoma	0.000734	0.0119	CbGeAlD
Dasatinib—RIPK2—blood vessel—melanoma	0.000719	0.0117	CbGeAlD
Dasatinib—MYT1—head—melanoma	0.000696	0.0113	CbGeAlD
Dasatinib—MAPK14—hair follicle—melanoma	0.000684	0.0111	CbGeAlD
Dasatinib—EPHB2—retina—melanoma	0.000666	0.0108	CbGeAlD
Dasatinib—EPHB4—endothelium—melanoma	0.000659	0.0107	CbGeAlD
Dasatinib—EPHA8—eye—melanoma	0.000644	0.0104	CbGeAlD
Dasatinib—MAPK14—blood vessel—melanoma	0.000641	0.0104	CbGeAlD
Dasatinib—KIT—skin epidermis—melanoma	0.00063	0.0102	CbGeAlD
Dasatinib—MAP4K5—hair follicle—melanoma	0.00062	0.0101	CbGeAlD
Dasatinib—EPHB4—blood vessel—melanoma	0.000608	0.00985	CbGeAlD
Dasatinib—JAK2—blood vessel—melanoma	0.000604	0.00978	CbGeAlD
Dasatinib—BMX—skin of body—melanoma	0.000598	0.00969	CbGeAlD
Dasatinib—EPHA2—blood vessel—melanoma	0.000596	0.00966	CbGeAlD
Dasatinib—YES1—hair follicle—melanoma	0.000573	0.00928	CbGeAlD
Dasatinib—EPHA3—eye—melanoma	0.000563	0.00913	CbGeAlD
Dasatinib—PTK6—skin of body—melanoma	0.000561	0.00908	CbGeAlD
Dasatinib—SRC—endothelium—melanoma	0.00056	0.00908	CbGeAlD
Dasatinib—PKMYT1—mammalian vulva—melanoma	0.000559	0.00906	CbGeAlD
Dasatinib—EPHA3—retina—melanoma	0.000558	0.00904	CbGeAlD
Dasatinib—STAT5B—skin of body—melanoma	0.00053	0.00859	CbGeAlD
Dasatinib—SRC—blood vessel—melanoma	0.000517	0.00838	CbGeAlD
Dasatinib—PTK6—mammalian vulva—melanoma	0.000511	0.00828	CbGeAlD
Dasatinib—ZAK—eye—melanoma	0.000509	0.00825	CbGeAlD
Dasatinib—EPHA5—eye—melanoma	0.000498	0.00808	CbGeAlD
Dasatinib—EPHA5—retina—melanoma	0.000494	0.008	CbGeAlD
Dasatinib—STAT5B—mammalian vulva—melanoma	0.000483	0.00783	CbGeAlD
Dasatinib—EPHB1—head—melanoma	0.000465	0.00753	CbGeAlD
Dasatinib—MAPK14—neck—melanoma	0.000459	0.00743	CbGeAlD
Dasatinib—KIT—endothelium—melanoma	0.000457	0.0074	CbGeAlD
Dasatinib—TESK1—eye—melanoma	0.00045	0.0073	CbGeAlD
Dasatinib—KIT—blood vessel—melanoma	0.000421	0.00683	CbGeAlD
Dasatinib—TEC—lymph node—melanoma	0.000415	0.00672	CbGeAlD
Dasatinib—CSK—eye—melanoma	0.000412	0.00668	CbGeAlD
Dasatinib—PDGFRB—blood vessel—melanoma	0.000412	0.00667	CbGeAlD
Dasatinib—SIK2—head—melanoma	0.00041	0.00665	CbGeAlD
Dasatinib—ZAK—mammalian vulva—melanoma	0.000404	0.00655	CbGeAlD
Dasatinib—PKMYT1—head—melanoma	0.0004	0.00648	CbGeAlD
Dasatinib—BTK—mammalian vulva—melanoma	0.000386	0.00625	CbGeAlD
Dasatinib—RIPK2—eye—melanoma	0.000383	0.0062	CbGeAlD
Dasatinib—EPHB2—head—melanoma	0.000382	0.00618	CbGeAlD
Dasatinib—RIPK2—retina—melanoma	0.000379	0.00615	CbGeAlD
Dasatinib—SRMS—head—melanoma	0.000373	0.00605	CbGeAlD
Dasatinib—TXK—head—melanoma	0.000369	0.00599	CbGeAlD
Dasatinib—EPHA8—head—melanoma	0.000366	0.00593	CbGeAlD
Dasatinib—STK35—skin of body—melanoma	0.000361	0.00585	CbGeAlD
Dasatinib—CSK—skin of body—melanoma	0.000359	0.00582	CbGeAlD
Dasatinib—TESK1—mammalian vulva—melanoma	0.000357	0.00579	CbGeAlD
Dasatinib—STK36—mammalian vulva—melanoma	0.000352	0.0057	CbGeAlD
Dasatinib—EPHB3—mammalian vulva—melanoma	0.000352	0.0057	CbGeAlD
Dasatinib—STAT5B—head—melanoma	0.000346	0.0056	CbGeAlD
Dasatinib—LIMK2—mammalian vulva—melanoma	0.00034	0.00551	CbGeAlD
Dasatinib—RIPK2—skin of body—melanoma	0.000333	0.0054	CbGeAlD
Dasatinib—CYP1B1—hair follicle—melanoma	0.000331	0.00537	CbGeAlD
Dasatinib—FMO3—eye—melanoma	0.000328	0.00532	CbGeAlD
Dasatinib—CYP1A1—skin epidermis—melanoma	0.000328	0.00532	CbGeAlD
Dasatinib—CSK—mammalian vulva—melanoma	0.000327	0.0053	CbGeAlD
Dasatinib—EPHB1—lymph node—melanoma	0.000325	0.00527	CbGeAlD
Dasatinib—SIK1—skin of body—melanoma	0.000325	0.00527	CbGeAlD
Dasatinib—HCK—mammalian vulva—melanoma	0.000323	0.00524	CbGeAlD
Dasatinib—EPHA3—head—melanoma	0.00032	0.00518	CbGeAlD
Dasatinib—ERBB3—skin of body—melanoma	0.000319	0.00517	CbGeAlD
Dasatinib—SIK3—head—melanoma	0.000311	0.00504	CbGeAlD
Dasatinib—KIT—neck—melanoma	0.000301	0.00488	CbGeAlD
Dasatinib—MAPK14—skin of body—melanoma	0.000297	0.00481	CbGeAlD
Dasatinib—SIK1—mammalian vulva—melanoma	0.000297	0.00481	CbGeAlD
Dasatinib—PDGFRB—neck—melanoma	0.000294	0.00477	CbGeAlD
Dasatinib—EPHA4—mammalian vulva—melanoma	0.000294	0.00476	CbGeAlD
Dasatinib—ZAK—head—melanoma	0.000289	0.00469	CbGeAlD
Dasatinib—YES1—eye—melanoma	0.000286	0.00463	CbGeAlD
Dasatinib—YES1—retina—melanoma	0.000283	0.00459	CbGeAlD
Dasatinib—EPHA5—head—melanoma	0.000283	0.00459	CbGeAlD
Dasatinib—LYN—head—melanoma	0.000281	0.00456	CbGeAlD
Dasatinib—JAK2—skin of body—melanoma	0.000279	0.00453	CbGeAlD
Dasatinib—MAP3K19—head—melanoma	0.000277	0.00449	CbGeAlD
Dasatinib—BMPR1B—head—melanoma	0.000277	0.00449	CbGeAlD
Dasatinib—FYN—skin of body—melanoma	0.000276	0.00447	CbGeAlD
Dasatinib—SRC—eye—melanoma	0.000275	0.00446	CbGeAlD
Dasatinib—BMX—lymph node—melanoma	0.000273	0.00443	CbGeAlD
Dasatinib—SRC—retina—melanoma	0.000273	0.00442	CbGeAlD
Dasatinib—TNK2—head—melanoma	0.000272	0.00441	CbGeAlD
Dasatinib—BLK—lymph node—melanoma	0.00027	0.00438	CbGeAlD
Dasatinib—FGR—mammalian vulva—melanoma	0.00027	0.00437	CbGeAlD
Dasatinib—LCK—mammalian vulva—melanoma	0.00027	0.00437	CbGeAlD
Dasatinib—MAP3K3—skin of body—melanoma	0.000269	0.00436	CbGeAlD
Dasatinib—FMO3—mammalian vulva—melanoma	0.00026	0.00422	CbGeAlD
Dasatinib—TXK—lymph node—melanoma	0.000259	0.00419	CbGeAlD
Dasatinib—EPHB6—skin of body—melanoma	0.000257	0.00417	CbGeAlD
Dasatinib—EPHB4—mammalian vulva—melanoma	0.000257	0.00416	CbGeAlD
Dasatinib—TESK1—head—melanoma	0.000256	0.00414	CbGeAlD
Dasatinib—JAK2—mammalian vulva—melanoma	0.000255	0.00413	CbGeAlD
Dasatinib—EPHA2—mammalian vulva—melanoma	0.000252	0.00408	CbGeAlD
Dasatinib—EPHB3—head—melanoma	0.000252	0.00408	CbGeAlD
Dasatinib—STK36—head—melanoma	0.000252	0.00408	CbGeAlD
Dasatinib—FYN—mammalian vulva—melanoma	0.000251	0.00407	CbGeAlD
Dasatinib—CSF1R—eye—melanoma	0.000247	0.004	CbGeAlD
Dasatinib—MAP4K5—mammalian vulva—melanoma	0.000246	0.00398	CbGeAlD
Dasatinib—MAP3K3—mammalian vulva—melanoma	0.000246	0.00398	CbGeAlD
Dasatinib—LIMK2—head—melanoma	0.000243	0.00394	CbGeAlD
Dasatinib—STAT5B—lymph node—melanoma	0.000242	0.00392	CbGeAlD
Dasatinib—SRC—skin of body—melanoma	0.000239	0.00388	CbGeAlD
Dasatinib—STK35—head—melanoma	0.000236	0.00382	CbGeAlD
Dasatinib—EPHB6—mammalian vulva—melanoma	0.000235	0.0038	CbGeAlD
Dasatinib—CSK—head—melanoma	0.000234	0.00379	CbGeAlD
Dasatinib—HCK—head—melanoma	0.000231	0.00375	CbGeAlD
Dasatinib—YES1—mammalian vulva—melanoma	0.000227	0.00368	CbGeAlD
Dasatinib—EPHA3—lymph node—melanoma	0.000224	0.00363	CbGeAlD
Dasatinib—PDGFRB—eye—melanoma	0.000219	0.00355	CbGeAlD
Dasatinib—SIK3—lymph node—melanoma	0.000218	0.00353	CbGeAlD
Dasatinib—RIPK2—head—melanoma	0.000217	0.00352	CbGeAlD
Dasatinib—CSF1R—skin of body—melanoma	0.000215	0.00348	CbGeAlD
Dasatinib—SIK1—head—melanoma	0.000212	0.00344	CbGeAlD
Dasatinib—EPHA4—head—melanoma	0.00021	0.0034	CbGeAlD
Dasatinib—ERBB3—head—melanoma	0.000208	0.00337	CbGeAlD
Dasatinib—MAP3K2—head—melanoma	0.000206	0.00334	CbGeAlD
Dasatinib—ZAK—lymph node—melanoma	0.000202	0.00328	CbGeAlD
Dasatinib—MAP2K5—mammalian vulva—melanoma	0.000201	0.00325	CbGeAlD
Dasatinib—CSF1R—mammalian vulva—melanoma	0.000196	0.00317	CbGeAlD
Dasatinib—ABL1—eye—melanoma	0.000195	0.00316	CbGeAlD
Dasatinib—KIT—skin of body—melanoma	0.000195	0.00316	CbGeAlD
Dasatinib—BMPR1B—lymph node—melanoma	0.000194	0.00315	CbGeAlD
Dasatinib—MAPK14—head—melanoma	0.000194	0.00314	CbGeAlD
Dasatinib—ABL1—retina—melanoma	0.000193	0.00313	CbGeAlD
Dasatinib—BTK—lymph node—melanoma	0.000193	0.00313	CbGeAlD
Dasatinib—FGR—head—melanoma	0.000193	0.00313	CbGeAlD
Dasatinib—PDGFRB—skin of body—melanoma	0.000191	0.00309	CbGeAlD
Dasatinib—TNK2—lymph node—melanoma	0.00019	0.00308	CbGeAlD
Dasatinib—FMO3—head—melanoma	0.000186	0.00302	CbGeAlD
Dasatinib—JAK2—head—melanoma	0.000182	0.00295	CbGeAlD
Dasatinib—EPHA2—head—melanoma	0.00018	0.00292	CbGeAlD
Dasatinib—FYN—head—melanoma	0.00018	0.00291	CbGeAlD
Dasatinib—TESK1—lymph node—melanoma	0.000179	0.0029	CbGeAlD
Dasatinib—KIT—mammalian vulva—melanoma	0.000178	0.00288	CbGeAlD
Dasatinib—EPHB3—lymph node—melanoma	0.000176	0.00285	CbGeAlD
Dasatinib—STK36—lymph node—melanoma	0.000176	0.00285	CbGeAlD
Dasatinib—MAP3K3—head—melanoma	0.000176	0.00285	CbGeAlD
Dasatinib—MAP4K5—head—melanoma	0.000176	0.00285	CbGeAlD
Dasatinib—PDGFRB—mammalian vulva—melanoma	0.000174	0.00282	CbGeAlD
Dasatinib—LIMK2—lymph node—melanoma	0.00017	0.00276	CbGeAlD
Dasatinib—ABL1—skin of body—melanoma	0.00017	0.00275	CbGeAlD
Dasatinib—EPHB6—head—melanoma	0.000168	0.00272	CbGeAlD
Dasatinib—CYP1B1—eye—melanoma	0.000165	0.00268	CbGeAlD
Dasatinib—STK35—lymph node—melanoma	0.000165	0.00267	CbGeAlD
Dasatinib—CSK—lymph node—melanoma	0.000164	0.00266	CbGeAlD
Dasatinib—YES1—head—melanoma	0.000162	0.00263	CbGeAlD
Dasatinib—HCK—lymph node—melanoma	0.000162	0.00262	CbGeAlD
Dasatinib—ABL2—lymph node—melanoma	0.000161	0.00261	CbGeAlD
Dasatinib—PDGFRA—head—melanoma	0.000159	0.00258	CbGeAlD
Dasatinib—SRC—head—melanoma	0.000156	0.00253	CbGeAlD
Dasatinib—ABL1—mammalian vulva—melanoma	0.000155	0.00251	CbGeAlD
Dasatinib—RIPK2—lymph node—melanoma	0.000152	0.00247	CbGeAlD
Dasatinib—SIK1—lymph node—melanoma	0.000149	0.00241	CbGeAlD
Dasatinib—EPHA4—lymph node—melanoma	0.000147	0.00238	CbGeAlD
Dasatinib—ERBB3—lymph node—melanoma	0.000146	0.00236	CbGeAlD
Dasatinib—MAP3K2—lymph node—melanoma	0.000144	0.00234	CbGeAlD
Dasatinib—CYP1B1—skin of body—melanoma	0.000144	0.00233	CbGeAlD
Dasatinib—MAP2K5—head—melanoma	0.000144	0.00233	CbGeAlD
Dasatinib—CSF1R—head—melanoma	0.00014	0.00227	CbGeAlD
Dasatinib—MAPK14—lymph node—melanoma	0.000136	0.0022	CbGeAlD
Dasatinib—FGR—lymph node—melanoma	0.000135	0.00219	CbGeAlD
Dasatinib—LCK—lymph node—melanoma	0.000135	0.00219	CbGeAlD
Dasatinib—FMO3—lymph node—melanoma	0.00013	0.00211	CbGeAlD
Dasatinib—EPHB4—lymph node—melanoma	0.000129	0.00208	CbGeAlD
Dasatinib—JAK2—lymph node—melanoma	0.000128	0.00207	CbGeAlD
Dasatinib—KIT—head—melanoma	0.000127	0.00206	CbGeAlD
Dasatinib—EPHA2—lymph node—melanoma	0.000126	0.00204	CbGeAlD
Dasatinib—FYN—lymph node—melanoma	0.000126	0.00204	CbGeAlD
Dasatinib—PDGFRB—head—melanoma	0.000124	0.00201	CbGeAlD
Dasatinib—MAP3K3—lymph node—melanoma	0.000123	0.00199	CbGeAlD
Dasatinib—MAP4K5—lymph node—melanoma	0.000123	0.00199	CbGeAlD
Dasatinib—EPHB6—lymph node—melanoma	0.000118	0.00191	CbGeAlD
Dasatinib—Ill-defined disorder—Bleomycin—melanoma	0.000117	0.0013	CcSEcCtD
Dasatinib—Anaemia—Bleomycin—melanoma	0.000116	0.00129	CcSEcCtD
Dasatinib—Diarrhoea—Vemurafenib—melanoma	0.000116	0.00129	CcSEcCtD
Dasatinib—Erythema multiforme—Temozolomide—melanoma	0.000115	0.00128	CcSEcCtD
Dasatinib—ABCB1—blood vessel—melanoma	0.000114	0.00185	CbGeAlD
Dasatinib—Eye disorder—Temozolomide—melanoma	0.000114	0.00127	CcSEcCtD
Dasatinib—Tinnitus—Temozolomide—melanoma	0.000114	0.00126	CcSEcCtD
Dasatinib—YES1—lymph node—melanoma	0.000114	0.00184	CbGeAlD
Dasatinib—Malaise—Bleomycin—melanoma	0.000114	0.00126	CcSEcCtD
Dasatinib—Flushing—Temozolomide—melanoma	0.000113	0.00126	CcSEcCtD
Dasatinib—Cardiac disorder—Temozolomide—melanoma	0.000113	0.00126	CcSEcCtD
Dasatinib—Arrhythmia—Carmustine—melanoma	0.000113	0.00125	CcSEcCtD
Dasatinib—Dizziness—Vemurafenib—melanoma	0.000112	0.00125	CcSEcCtD
Dasatinib—Alopecia—Carmustine—melanoma	0.000112	0.00124	CcSEcCtD
Dasatinib—PDGFRA—lymph node—melanoma	0.000111	0.00181	CbGeAlD
Dasatinib—ABL1—head—melanoma	0.000111	0.0018	CbGeAlD
Dasatinib—Angiopathy—Temozolomide—melanoma	0.000111	0.00123	CcSEcCtD
Dasatinib—Mental disorder—Carmustine—melanoma	0.000111	0.00123	CcSEcCtD
Dasatinib—Immune system disorder—Temozolomide—melanoma	0.00011	0.00122	CcSEcCtD
Dasatinib—Mediastinal disorder—Temozolomide—melanoma	0.00011	0.00122	CcSEcCtD
Dasatinib—Erythema—Carmustine—melanoma	0.00011	0.00122	CcSEcCtD
Dasatinib—Malnutrition—Carmustine—melanoma	0.00011	0.00122	CcSEcCtD
Dasatinib—Cough—Bleomycin—melanoma	0.00011	0.00122	CcSEcCtD
Dasatinib—Chills—Temozolomide—melanoma	0.000109	0.00122	CcSEcCtD
Dasatinib—SRC—lymph node—melanoma	0.000109	0.00177	CbGeAlD
Dasatinib—Ill-defined disorder—Dactinomycin—melanoma	0.000109	0.00121	CcSEcCtD
Dasatinib—Anaemia—Dactinomycin—melanoma	0.000109	0.00121	CcSEcCtD
Dasatinib—Vomiting—Vemurafenib—melanoma	0.000108	0.0012	CcSEcCtD
Dasatinib—Alopecia—Temozolomide—melanoma	0.000108	0.0012	CcSEcCtD
Dasatinib—Dry skin—Docetaxel—melanoma	0.000107	0.00119	CcSEcCtD
Dasatinib—Myalgia—Bleomycin—melanoma	0.000107	0.00119	CcSEcCtD
Dasatinib—Chest pain—Bleomycin—melanoma	0.000107	0.00119	CcSEcCtD
Dasatinib—Rash—Vemurafenib—melanoma	0.000107	0.00119	CcSEcCtD
Dasatinib—Mental disorder—Temozolomide—melanoma	0.000107	0.00119	CcSEcCtD
Dasatinib—Dermatitis—Vemurafenib—melanoma	0.000107	0.00119	CcSEcCtD
Dasatinib—Headache—Vemurafenib—melanoma	0.000106	0.00118	CcSEcCtD
Dasatinib—Erythema—Temozolomide—melanoma	0.000106	0.00118	CcSEcCtD
Dasatinib—Malnutrition—Temozolomide—melanoma	0.000106	0.00118	CcSEcCtD
Dasatinib—Breast disorder—Docetaxel—melanoma	0.000106	0.00118	CcSEcCtD
Dasatinib—Discomfort—Bleomycin—melanoma	0.000106	0.00118	CcSEcCtD
Dasatinib—Malaise—Dactinomycin—melanoma	0.000106	0.00118	CcSEcCtD
Dasatinib—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000106	0.00117	CcSEcCtD
Dasatinib—Dysgeusia—Temozolomide—melanoma	0.000104	0.00116	CcSEcCtD
Dasatinib—Confusional state—Bleomycin—melanoma	0.000104	0.00115	CcSEcCtD
Dasatinib—Vision blurred—Carmustine—melanoma	0.000104	0.00115	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Docetaxel—melanoma	0.000103	0.00115	CcSEcCtD
Dasatinib—Tremor—Carmustine—melanoma	0.000103	0.00114	CcSEcCtD
Dasatinib—Oedema—Bleomycin—melanoma	0.000103	0.00114	CcSEcCtD
Dasatinib—Infection—Bleomycin—melanoma	0.000102	0.00113	CcSEcCtD
Dasatinib—CYP1A1—skin of body—melanoma	0.000102	0.00165	CbGeAlD
Dasatinib—Anaemia—Carmustine—melanoma	0.000102	0.00113	CcSEcCtD
Dasatinib—Dysphagia—Docetaxel—melanoma	0.000101	0.00113	CcSEcCtD
Dasatinib—Nausea—Vemurafenib—melanoma	0.000101	0.00112	CcSEcCtD
Dasatinib—Thrombocytopenia—Bleomycin—melanoma	0.000101	0.00112	CcSEcCtD
Dasatinib—MAP2K5—lymph node—melanoma	0.000101	0.00163	CbGeAlD
Dasatinib—Vision blurred—Temozolomide—melanoma	0.0001	0.00111	CcSEcCtD
Dasatinib—Myalgia—Dactinomycin—melanoma	0.0001	0.00111	CcSEcCtD
Dasatinib—Bronchospasm—Docetaxel—melanoma	9.97e-05	0.00111	CcSEcCtD
Dasatinib—Tremor—Temozolomide—melanoma	9.95e-05	0.00111	CcSEcCtD
Dasatinib—Discomfort—Dactinomycin—melanoma	9.88e-05	0.0011	CcSEcCtD
Dasatinib—Angina pectoris—Docetaxel—melanoma	9.87e-05	0.0011	CcSEcCtD
Dasatinib—Ill-defined disorder—Temozolomide—melanoma	9.85e-05	0.0011	CcSEcCtD
Dasatinib—Anaemia—Temozolomide—melanoma	9.81e-05	0.00109	CcSEcCtD
Dasatinib—CSF1R—lymph node—melanoma	9.81e-05	0.00159	CbGeAlD
Dasatinib—Anorexia—Bleomycin—melanoma	9.79e-05	0.00109	CcSEcCtD
Dasatinib—ABCG2—mammalian vulva—melanoma	9.77e-05	0.00158	CbGeAlD
Dasatinib—Pancytopenia—Docetaxel—melanoma	9.62e-05	0.00107	CcSEcCtD
Dasatinib—Hypotension—Bleomycin—melanoma	9.6e-05	0.00107	CcSEcCtD
Dasatinib—Oedema—Dactinomycin—melanoma	9.58e-05	0.00107	CcSEcCtD
Dasatinib—Malaise—Temozolomide—melanoma	9.58e-05	0.00106	CcSEcCtD
Dasatinib—Vertigo—Temozolomide—melanoma	9.54e-05	0.00106	CcSEcCtD
Dasatinib—Convulsion—Carmustine—melanoma	9.52e-05	0.00106	CcSEcCtD
Dasatinib—Infection—Dactinomycin—melanoma	9.52e-05	0.00106	CcSEcCtD
Dasatinib—Hypertension—Carmustine—melanoma	9.49e-05	0.00105	CcSEcCtD
Dasatinib—Neutropenia—Docetaxel—melanoma	9.48e-05	0.00105	CcSEcCtD
Dasatinib—Palpitations—Temozolomide—melanoma	9.38e-05	0.00104	CcSEcCtD
Dasatinib—CYP1B1—head—melanoma	9.38e-05	0.00152	CbGeAlD
Dasatinib—Thrombocytopenia—Dactinomycin—melanoma	9.38e-05	0.00104	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Bleomycin—melanoma	9.36e-05	0.00104	CcSEcCtD
Dasatinib—Chest pain—Carmustine—melanoma	9.36e-05	0.00104	CcSEcCtD
Dasatinib—Myalgia—Carmustine—melanoma	9.36e-05	0.00104	CcSEcCtD
Dasatinib—Anxiety—Carmustine—melanoma	9.32e-05	0.00104	CcSEcCtD
Dasatinib—CYP1A1—mammalian vulva—melanoma	9.27e-05	0.0015	CbGeAlD
Dasatinib—Cough—Temozolomide—melanoma	9.27e-05	0.00103	CcSEcCtD
Dasatinib—Weight increased—Docetaxel—melanoma	9.22e-05	0.00103	CcSEcCtD
Dasatinib—Convulsion—Temozolomide—melanoma	9.2e-05	0.00102	CcSEcCtD
Dasatinib—Weight decreased—Docetaxel—melanoma	9.17e-05	0.00102	CcSEcCtD
Dasatinib—Hypertension—Temozolomide—melanoma	9.17e-05	0.00102	CcSEcCtD
Dasatinib—Dyspnoea—Bleomycin—melanoma	9.16e-05	0.00102	CcSEcCtD
Dasatinib—Anorexia—Dactinomycin—melanoma	9.13e-05	0.00102	CcSEcCtD
Dasatinib—Pneumonia—Docetaxel—melanoma	9.09e-05	0.00101	CcSEcCtD
Dasatinib—Confusional state—Carmustine—melanoma	9.04e-05	0.00101	CcSEcCtD
Dasatinib—Myalgia—Temozolomide—melanoma	9.04e-05	0.00101	CcSEcCtD
Dasatinib—Arthralgia—Temozolomide—melanoma	9.04e-05	0.00101	CcSEcCtD
Dasatinib—Infestation NOS—Docetaxel—melanoma	9.04e-05	0.001	CcSEcCtD
Dasatinib—Infestation—Docetaxel—melanoma	9.04e-05	0.001	CcSEcCtD
Dasatinib—Anxiety—Temozolomide—melanoma	9.01e-05	0.001	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	8.98e-05	0.000998	CcSEcCtD
Dasatinib—Oedema—Carmustine—melanoma	8.97e-05	0.000997	CcSEcCtD
Dasatinib—Discomfort—Temozolomide—melanoma	8.93e-05	0.000993	CcSEcCtD
Dasatinib—Decreased appetite—Bleomycin—melanoma	8.93e-05	0.000993	CcSEcCtD
Dasatinib—KIT—lymph node—melanoma	8.91e-05	0.00144	CbGeAlD
Dasatinib—Infection—Carmustine—melanoma	8.91e-05	0.000991	CcSEcCtD
Dasatinib—Acute coronary syndrome—Docetaxel—melanoma	8.91e-05	0.00099	CcSEcCtD
Dasatinib—Renal failure—Docetaxel—melanoma	8.88e-05	0.000988	CcSEcCtD
Dasatinib—Myocardial infarction—Docetaxel—melanoma	8.86e-05	0.000985	CcSEcCtD
Dasatinib—Neuropathy peripheral—Docetaxel—melanoma	8.86e-05	0.000985	CcSEcCtD
Dasatinib—Stomatitis—Docetaxel—melanoma	8.81e-05	0.000979	CcSEcCtD
Dasatinib—Pain—Bleomycin—melanoma	8.79e-05	0.000977	CcSEcCtD
Dasatinib—Conjunctivitis—Docetaxel—melanoma	8.78e-05	0.000977	CcSEcCtD
Dasatinib—Thrombocytopenia—Carmustine—melanoma	8.78e-05	0.000976	CcSEcCtD
Dasatinib—Tachycardia—Carmustine—melanoma	8.75e-05	0.000973	CcSEcCtD
Dasatinib—Confusional state—Temozolomide—melanoma	8.74e-05	0.000972	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Dactinomycin—melanoma	8.73e-05	0.000971	CcSEcCtD
Dasatinib—PDGFRB—lymph node—melanoma	8.7e-05	0.00141	CbGeAlD
Dasatinib—Oedema—Temozolomide—melanoma	8.67e-05	0.000964	CcSEcCtD
Dasatinib—Infection—Temozolomide—melanoma	8.61e-05	0.000957	CcSEcCtD
Dasatinib—Anorexia—Carmustine—melanoma	8.55e-05	0.00095	CcSEcCtD
Dasatinib—Hepatobiliary disease—Docetaxel—melanoma	8.55e-05	0.00095	CcSEcCtD
Dasatinib—Epistaxis—Docetaxel—melanoma	8.52e-05	0.000948	CcSEcCtD
Dasatinib—Nervous system disorder—Temozolomide—melanoma	8.5e-05	0.000945	CcSEcCtD
Dasatinib—Thrombocytopenia—Temozolomide—melanoma	8.49e-05	0.000943	CcSEcCtD
Dasatinib—Feeling abnormal—Bleomycin—melanoma	8.47e-05	0.000941	CcSEcCtD
Dasatinib—Skin disorder—Temozolomide—melanoma	8.42e-05	0.000936	CcSEcCtD
Dasatinib—Hypotension—Carmustine—melanoma	8.38e-05	0.000932	CcSEcCtD
Dasatinib—Hyperhidrosis—Temozolomide—melanoma	8.38e-05	0.000931	CcSEcCtD
Dasatinib—Decreased appetite—Dactinomycin—melanoma	8.33e-05	0.000926	CcSEcCtD
Dasatinib—Fatigue—Dactinomycin—melanoma	8.26e-05	0.000918	CcSEcCtD
Dasatinib—Anorexia—Temozolomide—melanoma	8.26e-05	0.000918	CcSEcCtD
Dasatinib—Pain—Dactinomycin—melanoma	8.19e-05	0.000911	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Carmustine—melanoma	8.17e-05	0.000908	CcSEcCtD
Dasatinib—Urticaria—Bleomycin—melanoma	8.16e-05	0.000907	CcSEcCtD
Dasatinib—Haemoglobin—Docetaxel—melanoma	8.15e-05	0.000906	CcSEcCtD
Dasatinib—Body temperature increased—Bleomycin—melanoma	8.12e-05	0.000903	CcSEcCtD
Dasatinib—Hepatitis—Docetaxel—melanoma	8.11e-05	0.000902	CcSEcCtD
Dasatinib—Haemorrhage—Docetaxel—melanoma	8.11e-05	0.000902	CcSEcCtD
Dasatinib—Insomnia—Carmustine—melanoma	8.11e-05	0.000902	CcSEcCtD
Dasatinib—Urinary tract disorder—Docetaxel—melanoma	8.01e-05	0.000891	CcSEcCtD
Dasatinib—Dyspnoea—Carmustine—melanoma	8e-05	0.000889	CcSEcCtD
Dasatinib—Oedema peripheral—Docetaxel—melanoma	7.99e-05	0.000888	CcSEcCtD
Dasatinib—Somnolence—Carmustine—melanoma	7.97e-05	0.000886	CcSEcCtD
Dasatinib—Connective tissue disorder—Docetaxel—melanoma	7.97e-05	0.000886	CcSEcCtD
Dasatinib—Urethral disorder—Docetaxel—melanoma	7.95e-05	0.000884	CcSEcCtD
Dasatinib—Feeling abnormal—Dactinomycin—melanoma	7.9e-05	0.000878	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Temozolomide—melanoma	7.9e-05	0.000878	CcSEcCtD
Dasatinib—Insomnia—Temozolomide—melanoma	7.84e-05	0.000871	CcSEcCtD
Dasatinib—Gastrointestinal pain—Dactinomycin—melanoma	7.84e-05	0.000871	CcSEcCtD
Dasatinib—Visual impairment—Docetaxel—melanoma	7.82e-05	0.000869	CcSEcCtD
Dasatinib—Decreased appetite—Carmustine—melanoma	7.8e-05	0.000867	CcSEcCtD
Dasatinib—ABL1—lymph node—melanoma	7.76e-05	0.00126	CbGeAlD
Dasatinib—Gastrointestinal disorder—Carmustine—melanoma	7.74e-05	0.000861	CcSEcCtD
Dasatinib—Dyspnoea—Temozolomide—melanoma	7.73e-05	0.000859	CcSEcCtD
Dasatinib—Somnolence—Temozolomide—melanoma	7.7e-05	0.000857	CcSEcCtD
Dasatinib—Erythema multiforme—Docetaxel—melanoma	7.67e-05	0.000853	CcSEcCtD
Dasatinib—Constipation—Carmustine—melanoma	7.67e-05	0.000853	CcSEcCtD
Dasatinib—Pain—Carmustine—melanoma	7.67e-05	0.000853	CcSEcCtD
Dasatinib—Dyspepsia—Temozolomide—melanoma	7.63e-05	0.000848	CcSEcCtD
Dasatinib—Eye disorder—Docetaxel—melanoma	7.58e-05	0.000843	CcSEcCtD
Dasatinib—Abdominal pain—Dactinomycin—melanoma	7.57e-05	0.000842	CcSEcCtD
Dasatinib—Body temperature increased—Dactinomycin—melanoma	7.57e-05	0.000842	CcSEcCtD
Dasatinib—Hypersensitivity—Bleomycin—melanoma	7.57e-05	0.000842	CcSEcCtD
Dasatinib—Decreased appetite—Temozolomide—melanoma	7.53e-05	0.000838	CcSEcCtD
Dasatinib—Cardiac disorder—Docetaxel—melanoma	7.53e-05	0.000837	CcSEcCtD
Dasatinib—Flushing—Docetaxel—melanoma	7.53e-05	0.000837	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Temozolomide—melanoma	7.48e-05	0.000832	CcSEcCtD
Dasatinib—Fatigue—Temozolomide—melanoma	7.47e-05	0.000831	CcSEcCtD
Dasatinib—Constipation—Temozolomide—melanoma	7.41e-05	0.000824	CcSEcCtD
Dasatinib—Pain—Temozolomide—melanoma	7.41e-05	0.000824	CcSEcCtD
Dasatinib—Feeling abnormal—Carmustine—melanoma	7.39e-05	0.000822	CcSEcCtD
Dasatinib—Asthenia—Bleomycin—melanoma	7.37e-05	0.00082	CcSEcCtD
Dasatinib—Angiopathy—Docetaxel—melanoma	7.36e-05	0.000818	CcSEcCtD
Dasatinib—Gastrointestinal pain—Carmustine—melanoma	7.33e-05	0.000815	CcSEcCtD
Dasatinib—Immune system disorder—Docetaxel—melanoma	7.33e-05	0.000815	CcSEcCtD
Dasatinib—Mediastinal disorder—Docetaxel—melanoma	7.31e-05	0.000813	CcSEcCtD
Dasatinib—Chills—Docetaxel—melanoma	7.28e-05	0.000809	CcSEcCtD
Dasatinib—Pruritus—Bleomycin—melanoma	7.27e-05	0.000808	CcSEcCtD
Dasatinib—Arrhythmia—Docetaxel—melanoma	7.25e-05	0.000806	CcSEcCtD
Dasatinib—Alopecia—Docetaxel—melanoma	7.17e-05	0.000797	CcSEcCtD
Dasatinib—Feeling abnormal—Temozolomide—melanoma	7.14e-05	0.000794	CcSEcCtD
Dasatinib—Mental disorder—Docetaxel—melanoma	7.11e-05	0.00079	CcSEcCtD
Dasatinib—Abdominal pain—Carmustine—melanoma	7.09e-05	0.000788	CcSEcCtD
Dasatinib—Body temperature increased—Carmustine—melanoma	7.09e-05	0.000788	CcSEcCtD
Dasatinib—Gastrointestinal pain—Temozolomide—melanoma	7.09e-05	0.000788	CcSEcCtD
Dasatinib—Erythema—Docetaxel—melanoma	7.06e-05	0.000785	CcSEcCtD
Dasatinib—Malnutrition—Docetaxel—melanoma	7.06e-05	0.000785	CcSEcCtD
Dasatinib—Hypersensitivity—Dactinomycin—melanoma	7.06e-05	0.000785	CcSEcCtD
Dasatinib—Dysgeusia—Docetaxel—melanoma	6.92e-05	0.000769	CcSEcCtD
Dasatinib—Urticaria—Temozolomide—melanoma	6.88e-05	0.000765	CcSEcCtD
Dasatinib—Asthenia—Dactinomycin—melanoma	6.87e-05	0.000764	CcSEcCtD
Dasatinib—Body temperature increased—Temozolomide—melanoma	6.85e-05	0.000762	CcSEcCtD
Dasatinib—Abdominal pain—Temozolomide—melanoma	6.85e-05	0.000762	CcSEcCtD
Dasatinib—Muscle spasms—Docetaxel—melanoma	6.79e-05	0.000755	CcSEcCtD
Dasatinib—CYP1A1—head—melanoma	6.63e-05	0.00107	CbGeAlD
Dasatinib—Hypersensitivity—Carmustine—melanoma	6.61e-05	0.000735	CcSEcCtD
Dasatinib—CYP1B1—lymph node—melanoma	6.57e-05	0.00106	CbGeAlD
Dasatinib—Diarrhoea—Dactinomycin—melanoma	6.56e-05	0.000729	CcSEcCtD
Dasatinib—Vomiting—Bleomycin—melanoma	6.53e-05	0.000726	CcSEcCtD
Dasatinib—Anaemia—Docetaxel—melanoma	6.53e-05	0.000726	CcSEcCtD
Dasatinib—Rash—Bleomycin—melanoma	6.48e-05	0.00072	CcSEcCtD
Dasatinib—Dermatitis—Bleomycin—melanoma	6.47e-05	0.00072	CcSEcCtD
Dasatinib—Asthenia—Carmustine—melanoma	6.43e-05	0.000715	CcSEcCtD
Dasatinib—Hypersensitivity—Temozolomide—melanoma	6.39e-05	0.00071	CcSEcCtD
Dasatinib—Syncope—Docetaxel—melanoma	6.33e-05	0.000704	CcSEcCtD
Dasatinib—Palpitations—Docetaxel—melanoma	6.24e-05	0.000694	CcSEcCtD
Dasatinib—Asthenia—Temozolomide—melanoma	6.22e-05	0.000691	CcSEcCtD
Dasatinib—Loss of consciousness—Docetaxel—melanoma	6.21e-05	0.00069	CcSEcCtD
Dasatinib—Cough—Docetaxel—melanoma	6.16e-05	0.000685	CcSEcCtD
Dasatinib—Diarrhoea—Carmustine—melanoma	6.14e-05	0.000682	CcSEcCtD
Dasatinib—Pruritus—Temozolomide—melanoma	6.13e-05	0.000682	CcSEcCtD
Dasatinib—Convulsion—Docetaxel—melanoma	6.12e-05	0.00068	CcSEcCtD
Dasatinib—Nausea—Bleomycin—melanoma	6.1e-05	0.000678	CcSEcCtD
Dasatinib—Hypertension—Docetaxel—melanoma	6.1e-05	0.000678	CcSEcCtD
Dasatinib—Vomiting—Dactinomycin—melanoma	6.09e-05	0.000677	CcSEcCtD
Dasatinib—Rash—Dactinomycin—melanoma	6.04e-05	0.000672	CcSEcCtD
Dasatinib—ABCB1—retina—melanoma	6.01e-05	0.000975	CbGeAlD
Dasatinib—Myalgia—Docetaxel—melanoma	6.01e-05	0.000668	CcSEcCtD
Dasatinib—Chest pain—Docetaxel—melanoma	6.01e-05	0.000668	CcSEcCtD
Dasatinib—Arthralgia—Docetaxel—melanoma	6.01e-05	0.000668	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	5.97e-05	0.000664	CcSEcCtD
Dasatinib—Dizziness—Carmustine—melanoma	5.93e-05	0.000659	CcSEcCtD
Dasatinib—Diarrhoea—Temozolomide—melanoma	5.93e-05	0.000659	CcSEcCtD
Dasatinib—Confusional state—Docetaxel—melanoma	5.81e-05	0.000646	CcSEcCtD
Dasatinib—Oedema—Docetaxel—melanoma	5.76e-05	0.000641	CcSEcCtD
Dasatinib—Dizziness—Temozolomide—melanoma	5.73e-05	0.000637	CcSEcCtD
Dasatinib—Infection—Docetaxel—melanoma	5.73e-05	0.000637	CcSEcCtD
Dasatinib—Vomiting—Carmustine—melanoma	5.7e-05	0.000634	CcSEcCtD
Dasatinib—Nausea—Dactinomycin—melanoma	5.69e-05	0.000633	CcSEcCtD
Dasatinib—Shock—Docetaxel—melanoma	5.67e-05	0.00063	CcSEcCtD
Dasatinib—Rash—Carmustine—melanoma	5.65e-05	0.000629	CcSEcCtD
Dasatinib—Nervous system disorder—Docetaxel—melanoma	5.65e-05	0.000628	CcSEcCtD
Dasatinib—Dermatitis—Carmustine—melanoma	5.65e-05	0.000628	CcSEcCtD
Dasatinib—Thrombocytopenia—Docetaxel—melanoma	5.64e-05	0.000627	CcSEcCtD
Dasatinib—Tachycardia—Docetaxel—melanoma	5.62e-05	0.000625	CcSEcCtD
Dasatinib—Headache—Carmustine—melanoma	5.62e-05	0.000625	CcSEcCtD
Dasatinib—Skin disorder—Docetaxel—melanoma	5.6e-05	0.000622	CcSEcCtD
Dasatinib—Vomiting—Temozolomide—melanoma	5.51e-05	0.000613	CcSEcCtD
Dasatinib—Anorexia—Docetaxel—melanoma	5.49e-05	0.000611	CcSEcCtD
Dasatinib—Rash—Temozolomide—melanoma	5.46e-05	0.000608	CcSEcCtD
Dasatinib—Dermatitis—Temozolomide—melanoma	5.46e-05	0.000607	CcSEcCtD
Dasatinib—Headache—Temozolomide—melanoma	5.43e-05	0.000604	CcSEcCtD
Dasatinib—Hypotension—Docetaxel—melanoma	5.39e-05	0.000599	CcSEcCtD
Dasatinib—Nausea—Carmustine—melanoma	5.33e-05	0.000592	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Docetaxel—melanoma	5.25e-05	0.000584	CcSEcCtD
Dasatinib—Insomnia—Docetaxel—melanoma	5.21e-05	0.00058	CcSEcCtD
Dasatinib—Nausea—Temozolomide—melanoma	5.15e-05	0.000572	CcSEcCtD
Dasatinib—Dyspnoea—Docetaxel—melanoma	5.14e-05	0.000571	CcSEcCtD
Dasatinib—Somnolence—Docetaxel—melanoma	5.12e-05	0.00057	CcSEcCtD
Dasatinib—Dyspepsia—Docetaxel—melanoma	5.07e-05	0.000564	CcSEcCtD
Dasatinib—Decreased appetite—Docetaxel—melanoma	5.01e-05	0.000557	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Docetaxel—melanoma	4.98e-05	0.000553	CcSEcCtD
Dasatinib—Fatigue—Docetaxel—melanoma	4.97e-05	0.000552	CcSEcCtD
Dasatinib—Pain—Docetaxel—melanoma	4.93e-05	0.000548	CcSEcCtD
Dasatinib—Constipation—Docetaxel—melanoma	4.93e-05	0.000548	CcSEcCtD
Dasatinib—ABCG2—lymph node—melanoma	4.89e-05	0.000793	CbGeAlD
Dasatinib—ABCB1—mammalian vulva—melanoma	4.82e-05	0.00078	CbGeAlD
Dasatinib—Feeling abnormal—Docetaxel—melanoma	4.75e-05	0.000528	CcSEcCtD
Dasatinib—Gastrointestinal pain—Docetaxel—melanoma	4.71e-05	0.000524	CcSEcCtD
Dasatinib—CYP1A1—lymph node—melanoma	4.64e-05	0.000753	CbGeAlD
Dasatinib—Body temperature increased—Docetaxel—melanoma	4.56e-05	0.000507	CcSEcCtD
Dasatinib—Abdominal pain—Docetaxel—melanoma	4.56e-05	0.000507	CcSEcCtD
Dasatinib—Hypersensitivity—Docetaxel—melanoma	4.25e-05	0.000472	CcSEcCtD
Dasatinib—Asthenia—Docetaxel—melanoma	4.14e-05	0.00046	CcSEcCtD
Dasatinib—Pruritus—Docetaxel—melanoma	4.08e-05	0.000453	CcSEcCtD
Dasatinib—Diarrhoea—Docetaxel—melanoma	3.94e-05	0.000438	CcSEcCtD
Dasatinib—Dizziness—Docetaxel—melanoma	3.81e-05	0.000424	CcSEcCtD
Dasatinib—Vomiting—Docetaxel—melanoma	3.66e-05	0.000407	CcSEcCtD
Dasatinib—Rash—Docetaxel—melanoma	3.63e-05	0.000404	CcSEcCtD
Dasatinib—Dermatitis—Docetaxel—melanoma	3.63e-05	0.000404	CcSEcCtD
Dasatinib—Headache—Docetaxel—melanoma	3.61e-05	0.000401	CcSEcCtD
Dasatinib—ABCB1—head—melanoma	3.45e-05	0.000558	CbGeAlD
Dasatinib—Nausea—Docetaxel—melanoma	3.42e-05	0.000381	CcSEcCtD
Dasatinib—ABCB1—lymph node—melanoma	2.41e-05	0.000391	CbGeAlD
Dasatinib—YES1—Signaling Pathways—PIK3CA—melanoma	3.16e-07	1.89e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—melanoma	3.15e-07	1.89e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NFKB1—melanoma	3.15e-07	1.88e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—PIK3CA—melanoma	3.14e-07	1.88e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—melanoma	3.14e-07	1.88e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MMP9—melanoma	3.14e-07	1.88e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CDKN1A—melanoma	3.13e-07	1.87e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PPARG—melanoma	3.13e-07	1.87e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTEN—melanoma	3.12e-07	1.87e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—melanoma	3.11e-07	1.86e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NFKB1—melanoma	3.11e-07	1.86e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—STAT3—melanoma	3.09e-07	1.85e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—NRAS—melanoma	3.08e-07	1.84e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—melanoma	3.08e-07	1.84e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGF2—melanoma	3.08e-07	1.84e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MAPK1—melanoma	3.07e-07	1.84e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—melanoma	3.07e-07	1.84e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.07e-07	1.84e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—melanoma	3.07e-07	1.84e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—melanoma	3.06e-07	1.83e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—melanoma	3.06e-07	1.83e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—melanoma	3.05e-07	1.83e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—melanoma	3.05e-07	1.82e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—melanoma	3.05e-07	1.82e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—melanoma	3.05e-07	1.82e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—MAPK1—melanoma	3.04e-07	1.82e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—melanoma	3.04e-07	1.82e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL8—melanoma	3.04e-07	1.82e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NRAS—melanoma	3.04e-07	1.82e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—melanoma	3.04e-07	1.82e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—melanoma	3.04e-07	1.82e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—melanoma	3.02e-07	1.8e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CD—melanoma	3.01e-07	1.8e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—melanoma	3.01e-07	1.8e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GNA11—melanoma	3.01e-07	1.8e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—melanoma	3e-07	1.79e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—melanoma	2.98e-07	1.78e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—melanoma	2.98e-07	1.78e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NRAS—melanoma	2.98e-07	1.78e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ALB—melanoma	2.97e-07	1.78e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—melanoma	2.97e-07	1.78e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1B—melanoma	2.97e-07	1.78e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—melanoma	2.97e-07	1.77e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—melanoma	2.96e-07	1.77e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MAPK3—melanoma	2.95e-07	1.77e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—FASN—melanoma	2.95e-07	1.76e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—melanoma	2.94e-07	1.76e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—melanoma	2.94e-07	1.76e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NRAS—melanoma	2.93e-07	1.75e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—melanoma	2.93e-07	1.75e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—melanoma	2.93e-07	1.75e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—melanoma	2.92e-07	1.75e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK3—melanoma	2.91e-07	1.74e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—melanoma	2.91e-07	1.74e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—melanoma	2.91e-07	1.74e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—melanoma	2.91e-07	1.74e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—melanoma	2.9e-07	1.74e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC5A5—melanoma	2.9e-07	1.73e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MDM2—melanoma	2.88e-07	1.72e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—melanoma	2.87e-07	1.72e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—melanoma	2.87e-07	1.72e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ABCB1—melanoma	2.86e-07	1.71e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—melanoma	2.86e-07	1.71e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK3—melanoma	2.85e-07	1.7e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CD—melanoma	2.85e-07	1.7e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—melanoma	2.84e-07	1.7e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—melanoma	2.83e-07	1.69e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—melanoma	2.83e-07	1.69e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—melanoma	2.83e-07	1.69e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NRAS—melanoma	2.82e-07	1.69e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—melanoma	2.82e-07	1.69e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—melanoma	2.82e-07	1.69e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—melanoma	2.82e-07	1.69e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ALB—melanoma	2.81e-07	1.68e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MAPK1—melanoma	2.81e-07	1.68e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—melanoma	2.81e-07	1.68e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK3—melanoma	2.81e-07	1.68e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CTNNB1—melanoma	2.8e-07	1.68e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—melanoma	2.8e-07	1.68e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—melanoma	2.8e-07	1.68e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CB—melanoma	2.8e-07	1.68e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GNAQ—melanoma	2.8e-07	1.68e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CD44—melanoma	2.8e-07	1.68e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—melanoma	2.79e-07	1.67e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—melanoma	2.79e-07	1.67e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NRAS—melanoma	2.78e-07	1.67e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—melanoma	2.78e-07	1.67e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—melanoma	2.78e-07	1.66e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—melanoma	2.77e-07	1.66e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK1—melanoma	2.77e-07	1.66e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—melanoma	2.77e-07	1.66e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—melanoma	2.76e-07	1.65e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—melanoma	2.75e-07	1.65e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—melanoma	2.75e-07	1.65e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1A—melanoma	2.74e-07	1.64e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—melanoma	2.73e-07	1.64e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—melanoma	2.73e-07	1.63e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—melanoma	2.73e-07	1.63e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NFKB1—melanoma	2.72e-07	1.63e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK1—melanoma	2.71e-07	1.62e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—melanoma	2.71e-07	1.62e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—melanoma	2.7e-07	1.62e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK3—melanoma	2.7e-07	1.62e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL8—melanoma	2.69e-07	1.61e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1B1—melanoma	2.68e-07	1.61e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK1—melanoma	2.67e-07	1.6e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—melanoma	2.67e-07	1.6e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—melanoma	2.67e-07	1.6e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK3—melanoma	2.67e-07	1.6e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—melanoma	2.65e-07	1.59e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—melanoma	2.64e-07	1.58e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—melanoma	2.64e-07	1.58e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PRKCA—melanoma	2.64e-07	1.58e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1B—melanoma	2.63e-07	1.57e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—melanoma	2.63e-07	1.57e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CB—melanoma	2.63e-07	1.57e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—melanoma	2.62e-07	1.56e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ERCC2—melanoma	2.61e-07	1.56e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—melanoma	2.61e-07	1.56e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—melanoma	2.6e-07	1.56e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—melanoma	2.59e-07	1.55e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CG—melanoma	2.59e-07	1.55e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—melanoma	2.58e-07	1.54e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—melanoma	2.58e-07	1.54e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—melanoma	2.58e-07	1.54e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—melanoma	2.57e-07	1.54e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK1—melanoma	2.57e-07	1.54e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—melanoma	2.57e-07	1.54e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—melanoma	2.57e-07	1.54e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—melanoma	2.56e-07	1.53e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—melanoma	2.55e-07	1.52e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK1—melanoma	2.54e-07	1.52e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—melanoma	2.54e-07	1.52e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—melanoma	2.52e-07	1.51e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—melanoma	2.51e-07	1.5e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARG—melanoma	2.5e-07	1.49e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—melanoma	2.5e-07	1.49e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CTNNB1—melanoma	2.48e-07	1.49e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CB—melanoma	2.48e-07	1.48e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—melanoma	2.47e-07	1.48e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—melanoma	2.47e-07	1.48e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—melanoma	2.46e-07	1.47e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—melanoma	2.46e-07	1.47e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—melanoma	2.44e-07	1.46e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—melanoma	2.44e-07	1.46e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NRAS—melanoma	2.44e-07	1.46e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—melanoma	2.44e-07	1.46e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—melanoma	2.44e-07	1.46e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—melanoma	2.44e-07	1.46e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—melanoma	2.43e-07	1.46e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—melanoma	2.43e-07	1.45e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1A—melanoma	2.43e-07	1.45e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—melanoma	2.42e-07	1.45e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NFKB1—melanoma	2.41e-07	1.44e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—melanoma	2.4e-07	1.44e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—melanoma	2.4e-07	1.43e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—melanoma	2.36e-07	1.41e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—melanoma	2.35e-07	1.41e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—melanoma	2.34e-07	1.4e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK3—melanoma	2.34e-07	1.4e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—melanoma	2.32e-07	1.39e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—melanoma	2.32e-07	1.39e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—melanoma	2.3e-07	1.38e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—melanoma	2.28e-07	1.36e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CD—melanoma	2.27e-07	1.36e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—melanoma	2.27e-07	1.36e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—melanoma	2.27e-07	1.36e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—melanoma	2.26e-07	1.35e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—melanoma	2.25e-07	1.35e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ALB—melanoma	2.24e-07	1.34e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—melanoma	2.24e-07	1.34e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—melanoma	2.23e-07	1.34e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—melanoma	2.23e-07	1.33e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—melanoma	2.22e-07	1.33e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK1—melanoma	2.22e-07	1.33e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—melanoma	2.22e-07	1.33e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ABCB1—melanoma	2.21e-07	1.32e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—melanoma	2.2e-07	1.32e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—melanoma	2.19e-07	1.31e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—melanoma	2.18e-07	1.3e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—melanoma	2.18e-07	1.3e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.17e-07	1.3e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—melanoma	2.16e-07	1.29e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRAS—melanoma	2.16e-07	1.29e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—melanoma	2.16e-07	1.29e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—melanoma	2.16e-07	1.29e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—melanoma	2.16e-07	1.29e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—melanoma	2.14e-07	1.28e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—melanoma	2.14e-07	1.28e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—melanoma	2.13e-07	1.27e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—melanoma	2.13e-07	1.27e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—melanoma	2.1e-07	1.26e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—melanoma	2.08e-07	1.25e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK3—melanoma	2.07e-07	1.24e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CG—melanoma	2.06e-07	1.24e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—melanoma	2.06e-07	1.23e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—melanoma	2.05e-07	1.23e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—melanoma	2.04e-07	1.22e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PRKCA—melanoma	2.03e-07	1.22e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ERCC2—melanoma	2.02e-07	1.21e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—melanoma	2.01e-07	1.2e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—melanoma	2.01e-07	1.2e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARG—melanoma	1.99e-07	1.19e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—melanoma	1.99e-07	1.19e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CB—melanoma	1.98e-07	1.19e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—melanoma	1.98e-07	1.18e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK1—melanoma	1.97e-07	1.18e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—melanoma	1.97e-07	1.18e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—melanoma	1.96e-07	1.17e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—melanoma	1.96e-07	1.17e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—melanoma	1.95e-07	1.17e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—melanoma	1.93e-07	1.15e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—melanoma	1.92e-07	1.15e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—melanoma	1.89e-07	1.13e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—melanoma	1.87e-07	1.12e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—melanoma	1.86e-07	1.11e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—melanoma	1.83e-07	1.09e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—melanoma	1.82e-07	1.09e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CD—melanoma	1.81e-07	1.09e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—melanoma	1.8e-07	1.08e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ALB—melanoma	1.79e-07	1.07e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—melanoma	1.78e-07	1.07e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—melanoma	1.71e-07	1.02e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—melanoma	1.71e-07	1.02e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—melanoma	1.71e-07	1.02e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—melanoma	1.65e-07	9.88e-07	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—melanoma	1.6e-07	9.58e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CG—melanoma	1.59e-07	9.53e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CB—melanoma	1.58e-07	9.46e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—melanoma	1.58e-07	9.45e-07	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—melanoma	1.58e-07	9.43e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—melanoma	1.57e-07	9.38e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARG—melanoma	1.54e-07	9.2e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—melanoma	1.51e-07	9.05e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—melanoma	1.51e-07	9.05e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CD—melanoma	1.4e-07	8.38e-07	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—melanoma	1.39e-07	8.34e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALB—melanoma	1.38e-07	8.27e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—melanoma	1.37e-07	8.18e-07	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—melanoma	1.31e-07	7.82e-07	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—melanoma	1.24e-07	7.39e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CB—melanoma	1.22e-07	7.3e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—melanoma	1.21e-07	7.24e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—melanoma	1.21e-07	7.23e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—melanoma	1.06e-07	6.31e-07	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—melanoma	9.87e-08	5.9e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—melanoma	9.64e-08	5.77e-07	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—melanoma	7.88e-08	4.71e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—melanoma	7.44e-08	4.45e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—melanoma	6.08e-08	3.64e-07	CbGpPWpGaD
